DBV Technologies to Attend Upcoming Investor Conferences
June 03 2019 - 1:30AM
Montrouge, France, June 3, 2019
DBV Technologies to Attend Upcoming
Investor Conferences
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that members of its
management team will present at the following investor conferences
in June 2019:
Kevin Trapp, Chief Commercial Officer, will
present at the Jefferies 2019 Global Healthcare Conference in New
York, NY, on Friday, June 7, 2019, at 9:30am ET.
Daniel Tassé, Chief Executive Officer, will
present at the Goldman Sachs 40th Annual Global Healthcare
Conference in Rancho Palos Verdes, CA, on Wednesday, June 12, 2019,
at 8:40am PT.
Daniel Tassé, Chief Executive Officer, will
present at the JMP Securities Life Sciences Conference in New York,
NY, on Wednesday, June 19, 2019, at 10:30am ET.
Live webcasts of the presentations at the
Jefferies 2019 Global Healthcare Conference, the Goldman Sachs 40th
Annual Global Healthcare Conference and the JMP Securities Life
Sciences Conference, will be available on the Investors & Media
section of the Company’s website:
https://www.dbv-technologies.com/investor-relations/. A replay of
the presentations will also be available on DBV’s website within
one hour after the events.
About DBV
Technologies
DBV Technologies is developing Viaskin®, a
proprietary technology platform with broad potential applications
in immunotherapy. Viaskin is based on epicutaneous immunotherapy,
or EPIT®, DBV’s method of delivering biologically active compounds
to the immune system through intact skin. With this new class of
self-administered and non-invasive product candidates, the Company
is dedicated to safely transforming the care of food allergic
patients, for whom there are no approved treatments. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut and Viaskin Milk, and preclinical development of Viaskin
Egg. DBV is also pursuing a human proof-of-concept clinical study
of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and
exploring potential applications of its platform in vaccines and
other immune diseases. DBV Technologies has global headquarters in
Montrouge, France and New York, NY. The Company’s ordinary shares
are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code:
FR0010417345), part of the SBF120 index, and the Company’s ADSs
(each representing one-half of one ordinary share) are traded on
the Nasdaq Global Select Market (Ticker: DBVT).
DBV Investor Relations ContactSara
Blum ShermanSenior Director, Investor Relations & Strategy
+1 212-271-0740sara.sherman@dbv-technologies.com
DBV Media Contact Joe Becker VP,
Global Corporate Communications+1-646-650-3912
joseph.becker@dbv-technologies.com
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Apr 2023 to Apr 2024